FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014040545> ?p ?o ?g. }

• W3014040545 endingPage "49" @default.
• W3014040545 startingPage "41" @default.
• W3014040545 abstract "The clinical trials of new anti-tumor drugs are prospering in China. The acceptance of clinical trials in patients is an important factor affecting the speed and quality of clinical trials. Previous studies have investigated the acceptance of clinical trials in those cancer patients, who have never participated in a trial. This study is designed to investigate and compare the acceptance and related causes of clinical trials in cancer patients who have once participated in a clinical trial or not.From June 2018 to April 2019, a standardized questionnaire-based survey was conducted among two groups of cancer patients classified by history of clinical trial participation in Cancer hospital, Chinese Academy of Medical Science, mainly focusing on their overall acceptance of clinical trials and related considerations, including the role of attending doctors, as well as group differences between the two participants.A total of 538 patients were enrolled with an average age of 53.5 years old, 51.1% of whom were males, and 43.3% of whom have never participated in a clinical trial. Overall, 502 patients (93.3%) were willing to or recommend their relatives or friends to participate in clinical trials, and patients with history of clinical trial participation had higher willingness (96.6% vs 90.8%, P=0.008). Patients were most likely to be motivated by expectation of optimal treatment (100.0% vs 99.3%) for both those who had once participated in a clinical trial or those not, respectively followed by financial burden reduction (56.0%) and recommendation by attending doctor (43.7%). The main reasons for unwillingness-to-participate for those who had once participated in a clinical trial were abandoning other treatment options, divided into control group or additional visits, while for those who had never participated in a clinical trial, ineffective treatment or serious adverse reactions were their main concerns. In the decision-making of clinical trial participation, 88% patients highly valued the role of recommendation by attending doctors. Among patients without trial participation history, 60.9% of those had no unwillingness-to-participate expressed that recommendation by attending doctors would change their decisions. The study also reported patients' preferences for information and access to clinical trials.The acceptance of clinical trials in cancer patients in our hospital is generally high, especially in patients who had a history of trial participation. It's of substantial significance to give full play to the role of doctors in improving the acceptance of clinical trials of cancer patients in China.【中文题目：肿瘤患者临床试验接受意愿及相关原因分析】 【中文摘要：背景与目的 我国的抗肿瘤新药临床试验开展如火如荼，患者的临床试验接受度是影响临床试验开展速度和质量的重要因素。既往研究仅针对未参与过临床试验的肿瘤患者接受度展开调查，未分析参加过临床试验患者的相关情况。本研究调查并比较参加过和未参与过试验的肿瘤患者对于临床试验的接受度，并分析相关原因。方法 2018年6月-2019年4月，采用标准化问卷在中国医学科学院肿瘤医院针对肿瘤患者（参加过 vs 未参加过试验）开展调查，分析比较两组患者临床试验的接受度和差异，并分析主要原因及医生对其接受度的影响。结果 共纳入538例患者，男性51.1%，平均年龄53.5岁，43.3%的患者参加过试验。总体而言，502例（93.3%）患者愿意参加或推荐亲友参加试验，参加过试验的患者接受度较高（96.6% vs 90.8%, P=0.008）。参加过和未参加过试验患者愿意的最主要原因均为“期待最佳治疗效果”（100.0% vs 99.3%），次要原因分别为“可减轻经济负担”（56.0%）和“主治医生建议”（43.7%）。参加过试验的患者不愿意参加的主要原因为“放弃其他治疗选择”、“分到对照治疗组”或“额外访视影响生活”；未参加过试验的患者为“治疗效果不佳”或“出现严重不良反应”。对参加过试验的患者，医生推荐对88%患者参与试验的决策起到关键作用；对未参加过试验的患者，医生推荐可使60.9%无参与意愿者改变其选择。研究也报告了患者对临床试验获取信息和途径等的倾向选择。结论 肿瘤患者临床试验接受度普遍较高，尤其是参加过试验的患者。充分发挥主治医生的作用对提高我国肿瘤患者临床试验接受度有重要意义。】 【中文关键词：肿瘤；临床试验；接受度；参与意愿】." @default.
• W3014040545 created "2020-04-03" @default.
• W3014040545 creator A5000084857 @default.
• W3014040545 creator A5004514476 @default.
• W3014040545 creator A5007110118 @default.
• W3014040545 creator A5011071426 @default.
• W3014040545 creator A5024433736 @default.
• W3014040545 creator A5027463111 @default.
• W3014040545 creator A5038784048 @default.
• W3014040545 creator A5043689338 @default.
• W3014040545 creator A5044375127 @default.
• W3014040545 creator A5049816813 @default.
• W3014040545 creator A5050495630 @default.
• W3014040545 creator A5053284682 @default.
• W3014040545 creator A5075198039 @default.
• W3014040545 creator A5079841820 @default.
• W3014040545 creator A5081433919 @default.
• W3014040545 date "2020-01-20" @default.
• W3014040545 modified "2023-10-13" @default.
• W3014040545 title "[Acceptance and Related Causes of Clinical Trials among Cancer Patients in China]." @default.
• W3014040545 cites W2075463597 @default.
• W3014040545 cites W2131325424 @default.
• W3014040545 cites W2230795721 @default.
• W3014040545 cites W2297694852 @default.
• W3014040545 cites W2604960917 @default.
• W3014040545 cites W2617276441 @default.
• W3014040545 cites W2889646458 @default.
• W3014040545 cites W2982337854 @default.
• W3014040545 cites W3013423117 @default.
• W3014040545 doi "https://doi.org/10.3779/j.issn.1009-3419.2020.01.07" @default.
• W3014040545 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7007398" @default.
• W3014040545 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31948537" @default.
• W3014040545 hasPublicationYear "2020" @default.
• W3014040545 type Work @default.
• W3014040545 sameAs 3014040545 @default.
• W3014040545 citedByCount "2" @default.
• W3014040545 countsByYear W30140405452020 @default.
• W3014040545 countsByYear W30140405452023 @default.
• W3014040545 crossrefType "journal-article" @default.
• W3014040545 hasAuthorship W3014040545A5000084857 @default.
• W3014040545 hasAuthorship W3014040545A5004514476 @default.
• W3014040545 hasAuthorship W3014040545A5007110118 @default.
• W3014040545 hasAuthorship W3014040545A5011071426 @default.
• W3014040545 hasAuthorship W3014040545A5024433736 @default.
• W3014040545 hasAuthorship W3014040545A5027463111 @default.
• W3014040545 hasAuthorship W3014040545A5038784048 @default.
• W3014040545 hasAuthorship W3014040545A5043689338 @default.
• W3014040545 hasAuthorship W3014040545A5044375127 @default.
• W3014040545 hasAuthorship W3014040545A5049816813 @default.
• W3014040545 hasAuthorship W3014040545A5050495630 @default.
• W3014040545 hasAuthorship W3014040545A5053284682 @default.
• W3014040545 hasAuthorship W3014040545A5075198039 @default.
• W3014040545 hasAuthorship W3014040545A5079841820 @default.
• W3014040545 hasAuthorship W3014040545A5081433919 @default.
• W3014040545 hasConcept C121608353 @default.
• W3014040545 hasConcept C126322002 @default.
• W3014040545 hasConcept C1862650 @default.
• W3014040545 hasConcept C2776256026 @default.
• W3014040545 hasConcept C502991105 @default.
• W3014040545 hasConcept C512399662 @default.
• W3014040545 hasConcept C535046627 @default.
• W3014040545 hasConcept C71924100 @default.
• W3014040545 hasConceptScore W3014040545C121608353 @default.
• W3014040545 hasConceptScore W3014040545C126322002 @default.
• W3014040545 hasConceptScore W3014040545C1862650 @default.
• W3014040545 hasConceptScore W3014040545C2776256026 @default.
• W3014040545 hasConceptScore W3014040545C502991105 @default.
• W3014040545 hasConceptScore W3014040545C512399662 @default.
• W3014040545 hasConceptScore W3014040545C535046627 @default.
• W3014040545 hasConceptScore W3014040545C71924100 @default.
• W3014040545 hasIssue "1" @default.
• W3014040545 hasLocation W30140405451 @default.
• W3014040545 hasLocation W30140405452 @default.
• W3014040545 hasOpenAccess W3014040545 @default.
• W3014040545 hasPrimaryLocation W30140405451 @default.
• W3014040545 hasRelatedWork W1575925512 @default.
• W3014040545 hasRelatedWork W1967103478 @default.
• W3014040545 hasRelatedWork W2032912323 @default.
• W3014040545 hasRelatedWork W2135322747 @default.
• W3014040545 hasRelatedWork W2188259592 @default.
• W3014040545 hasRelatedWork W2372561159 @default.
• W3014040545 hasRelatedWork W2375344515 @default.
• W3014040545 hasRelatedWork W2390152934 @default.
• W3014040545 hasRelatedWork W4206783359 @default.
• W3014040545 hasRelatedWork W4253419875 @default.
• W3014040545 hasVolume "23" @default.
• W3014040545 isParatext "false" @default.
• W3014040545 isRetracted "false" @default.
• W3014040545 magId "3014040545" @default.
• W3014040545 workType "article" @default.